The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBiohaven Ltd. (BHVN) has been downgraded from 'Strong Buy' to 'Hold' following a Complete Response Letter (CRL) from the FDA regarding its drug troriluzole for Spinocerebellar Ataxia. This regulatory setback has prompted the company to pivot its strategic focus toward other late-stage pipeline programs, including taldefgrobep alfa for obesity treatment. Investors are now looking toward the second half of 2026 for phase 2 proof-of-concept data on the obesity candidate. Additionally, the company is prioritizing its Kv7 activator, Opakalim, and its protein degrader platforms, BHV-1400 and BHV-1300. While previous analyst sentiment was highly bullish, the current shift reflects a more cautious outlook as the company navigates regulatory hurdles and extended data timelines.